Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Trial of CM-AT in Children With Autism
NCT00881452 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CM-AT
Study Locations (19)
California
- University of California, Davis, M.I.N.D. Institute — Sacramento
- University of California, San Francisco — San Francisco
- Neuropsychiatric Research Center of Orange County — Santa Ana
Pennsylvania
- Hershey Medical Center — Hershey
- Drexel University — Philadelphia
- University of Pittsburgh — Pittsburgh
Arizona
- Southwest Autism Research and Resource Center — Phoenix
Florida
- Lake Mary Pediatrics — Orange City
Georgia
- Institute for Behavioral Medicine — Smyrna
Illinois
- Alexian Brothers Center for Psychiatric Research — Hoffman Estates
Louisiana
- Louisiana State University Health Science Center — Shreveport
New Jersey
- Saint Peters University Hospital — New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-09 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881452
The ClinicalTrials.gov registry entry for NCT00881452 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Curemark, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Autism appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00881452 reports 19 study locations spanning 15 distinct geographic areas — top geographies include California, Pennsylvania, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00881452 about?
NCT00881452 is a clinical study titled "A Trial of CM-AT in Children With Autism". The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.
What is the current status of trial NCT00881452?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2009-05. Estimated completion is 2011-09.
What conditions does trial NCT00881452 study?
This clinical trial studies the following conditions: Autism. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00881452?
The interventions under investigation include: Placebo (DRUG), CM-AT (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00881452?
This trial is sponsored by Curemark, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00881452 being conducted?
This trial has 19 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.